Business Plan

DISCLAIMER
This presentation was prepared exclusively for the benefit and internal use, and is for the confidential
use only. Of those persons to whom it is presented or transmitted. This presentation is not and does
not form part of an offer, invitation or recommendation in respect of securities. The information
contained in this presentation is given without any liability whatsoever to MacKay Life Sciences,
Inc. (“MacKay” or the “Company”) or any of the Company’s respective directors, officers,
employees or agents, and such persons disclaim any liability whatsoever (including for negligence)
for any loss howsoever arising from any use of this presentation or its contents or otherwise arising
in connection therewith. This presentation is not intended to constitute legal, tax or accounting
advice or opinion. NO representation or warranty, expressed or implied, is made as to the accuracy,
completeness or thoroughness of the content of the information. The recipient should consult with its
own legal, tax or accounting advisers as to the accuracy and application of the information contained
herein and should conduct its own due diligence and other enquiries in relation to such information.
Reliance should not be placed on the information of the documents for any investment decision.

This presentation must not be disclosed to any other party and does not carry any right of
publication. This presentation is incomplete without reference to, and should be viewed solely in
conjunction with, the oral briefing provided by the Company. Neither this presentation nor any of its
contents may be reproduced or used for any other purpose without the prior written consent of the
Company.
2

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED

 EXECUTIVE SUMMARY
 Biofield Inc. (OTCBB: BZEC), has been renamed MacKay Life Sciences,
Inc. (“MacKay”)
 With over US$ 85 million invested in Research and Development, MacKay
is a medical technology company focused on engaged in identifying,
developing manufacturing, distributing and marketing non-invasive medical
devices to assist in the detection of cancer.
 According to World Health Organization (WHO), cancer is the leading
cause of death worldwide, and accounted for 7.4 million deaths in 2004,
(this figure represents around 13% of all deaths globally) with 70% of all
cancer deaths occurring in low- and middle-income countries. Deaths from
cancer worldwide are projected to continue rising, with an estimated 12
million annual deaths by 2030
 Today, the most common types of cancer worldwide are lung, stomach,
colorectal, liver, breast and cervical. WHO revealed that about one-third of
the cancer burden could be decreased if cases were detected earlier and
3
treated immediately

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED

 COMPANY OVERVIEW
 Our Vision
 MacKay – employs individuals from the highest echelons of science and
engineering in the fields of healthcare screening, diagnostics and treatment. The
Company’s ongoing commitment is to enhance quality of life through the
development and delivery of innovative medical procedures and products.
 MacKay is in a position to become the premier global provider of non-invasive
screening and diagnostic medical technologies for early cancer and illness
detection, most currently in the field of breast and cervical cancer.

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED

 ABOUT MACKAY LIFE SCIENCES
 MacKay, is a US based listed medical company which develops,
manufactures, seeks for and acquires non-invasive medical technologies in
detecting and preventing cancers and other illnesses. Today the Company
has reoriented and expanded its energies to focus on offering non-invasive
and cost effective technologies to the world’s population on an easily
accessible basis.
 The company currently:
 Owns a state-of-the-art technology in breast cancer – the Biofield Breast Cancer
Diagnostic System (“BDS”);
 Is a substantial shareholder in ValiBio – a subsidiary of an UK Alternative
Investment Market (AIM) listed company ValiRx Plc.

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED

 ABOUT VALIBIO
 ValiBio – a subsidiary of the AIM listed company ValiRx Plc, is a
biopharmaceutical company developing novel technologies and products in
oncology therapeutics and diagnostics.
 Current Prodcuts:
 NucleosomicsTM – blood tests for the early detection of cancer based on the
presence of epigenetic alternations to nucleosomes of blood in cancer patients;
 HypergenomicsTM – tissue biopsy tests for the differential, prognostic and
personalized medicine diagnostics of cancer based on the detection of epigenetic
alterations in chromatin structure – hypersensitive sites;
 HPV diagnostic test – Cervical cancer diagnostic test.

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED

 MILESTONE
Established Biofield Corporation, Inc.
Re-incorporated in Delaware, USA
Began Clinical Trials in Japan, Philippines, Malaysia, Europe, and the US
Listed in NASDAQ / Submitted FDA PMA Application / Stock price reached
US$ 33 per share (before the 10 to 1 reverse)
Appointed Dr. Long as Chairman & CEO
European CE Mark Approved
Began post market surveillance Evaluation
Mr. James MacKay acquired Biofield / Dr. Long passed away from cancer
MacKay sets up Headquarter in HK
MacKay signs Distribution Agreement for HK, Macau and Philippines / MacKay
opens its first Clinical Centre in Shanghai / Receives an upgrade from Pink Sheet
to OTC Bulletin Board (OTCBB: BZEC) / BDS downgraded to a non-invasive
Medical Device to Category IIA
Biofield acquires ValiBio and signs worldwide distribution rights for
NucleosomicsTM, HypergenomicsTM, and HPV / HK renowned oncologist Dr. Louis
Chow begins using BDS / MacKay Signs Distribution Agreement with Mexico,
Argentina and Brazil for US$ 3 Million / Begins Screening Clinical Trial in
Mexico and China / Applies for CE Mark and FDA 510K on Screening and
Diagnostic / Signs MOU for Distribution Rights to Russia, Turkey and Slovakia 7

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED

 PRODUCTS -
BIOFIELD DIAGNOSTIC SYSTEM (BDS)
 BDS is a non-invasive, radiation free, fast and
accurate diagnostic system for the detection of breast
cancer in women above 15 years of age. Its
technology is based on the differentiation of the
different electropotential currents produced during
cell differentiation and proliferation commonly
associated with cancer.
 BDS offers a series of distinct advantages:
 Completely non-invasive, radiation free, no compression and pain free.
 More accurate
 Detects up to 30% of cancers missed by other technologies such as mammograms.
 Detects smaller, deeper cancers especially in younger women.
 Less expensive than other current technologies.
 Completely portable and much easier to learn and operate.
 It is totally non-invasive and painless, allowing patient to avoid unnecessary biopsies,
which may be what deter some patient from seeking early detection in the first place.
8

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED

 PRODUCTS -
BIOFIELD DIAGNOSTIC SYSTEM (BDS) -
CONT. Unique Features
 BDS technology is far more effective than mammograms and other forms of
breast cancer diagnostic technology for a number of reasons including:
 Accuracy: BDS can detect up to 30% of cancers (especially small tumors in
younger women) missed by current technologies.
 Safe and Painless: BDS is non-invasive, painless and radiation free. The
procedure may be repeated as frequently as desired thus eliminating unnecessary
biopsies, which up until now may have attributed towards women not seeking
consultation on early detection through other means in the first place.
 Portability: BDS can be used in a physician’s office and is small enough to
transport to rural areas, creating opportunities for women who cannot visit a
hospital or major medical centers to be screened.
 Rapid Results: BDS provides accurate results immediately (15 minutes) and a
trained technician rather than a physician or radiologist can perform the
procedure.
 Cost to Patient: BDS is ten times less expensive than mammograms, ultrasound,
CT scans and MRIs.
 Cost to Physician: BDS is profitable to the physician yet testing can be priced
lower than diagnostic mammography and screening mammograms, with no
expensive training or other lab fees.
 Standalone Screening: Singapore re-analyzed the original US clinical trial data
conducted by Biofield and results show a very good sensitivity, specificity,
accuracy and ROC curve (AROC) by different statistical methods. This may
indicate that the BDS need not be dependent on mammogram, ultrasound or
physical examination and can be treated as a standalone screening device.

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED

 PRODUCTS -
VALIBIO: CERVICAL HPV INFECTION
SCREENING TEST

 The ValiBio High Risk Cervical HPV Infection

Screening Test is a CE marked automated test for
the 15 HPV subtype cervical infections considered
to be high risk for the development of cervical
cancer. In addition, the presence of either HPV
subtype 16 or 18, which are considered the highest
risks for cervical cancer and are the subtype targets
for anti-HPV vaccination programmes, are
separately detected and identified.
10

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED

 PRODUCTS -
VALIBIO: NUCLEOSOMICSTM DIAGNOSTIC
PRODUCTS
 NucleosomicsTM is a platform for non-invasive (blood) tests for early cancer
diagnosis based on epigenetic signal changes associated with malignancy.
 ELISA tests for global histone modifications expressed in cell free
nucleosomes in blood that are characteristic of cancers are currently under
development. The company expects to launch early NucleosomicsTM
products for research use in 2009. Diagnostic products regulated by EMEA
and the FDA will follow. Early disease focus is in lung, pancreatic and
colon cancer
 Unique feature:
 Using a small amount of blood to detect different kinds of cancers, which is
different from traditional screening methods such as PET / CT scan, CT scan and
MRI.
 A safe way to avoid radiation risks to medical personnel and staff
 Avoid time consuming and expensive costs.

11

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED

 PRODUCTS -
VALIBIO: HYPERGENOMICSTM DIAGNOSTIC
PRODUCTS
 HyperGenomicsTM is a platform for differential
diagnostic and prognostic tests in cancer as well as
testing for personalised medicine. Now focus is on
leukaemia, prostate and colon cancer.

 Unique feature:
 Detecting all hypersensitive sites in cells
Genome wide screening to identify all the hypersensitive sites present in cancer or
healthy tissue cells.
 One-off screening for result

By using ultra-sequencing all the hypersensitive sites present in several patient

samples can be screened in a single run.
 Distinguishing malignant cells

This technique is used to identify panels of hypersensitive sites present in aggressive

malignant cancer cells but absent in other cells.
12

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED

 MARKET OVERVIEW – BREAST CANCER
 Breast cancer is the most common malignancy in women and the second leading cause
of cancer death. Breast cancer diagnostics represents a US$6 billion global market.
 Breast cancer is three times more common than all gynecologic malignancies. The
incidence of breast cancer has been increasing steadily from an incidence of 1:20 in
1960 to 1:7 women today.
 The National Breast Cancer Foundation estimated that each year over 200,000 new
cases of breast cancer will be diagnosed and over 40,000 patients die from the disease.
 Breast cancer is considered to be a heterogeneous disease, meaning that it is a different
disease in different women, a different disease in different age groups and has different
cell populations within the tumor itself.
 Autopsy studies show that 2% of the female population has undiagnosed breast cancer
at the time of death.
 Nowadays, the most common methods currently being used for diagnosing breast cancer
are diagnostic mammography, ultrasound and biopsy.

13

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED

 MARKET OVERVIEW – BREAST CANCER
MAMMOGRAPHY
 Mammography is the process of emitting a low-dose X-ray
beam through a portion of the breast while the breast is
compressed between a plastic paddle and a film holder.
 The result is a black and white negative displaying the fatty
tissue, the ducts and lobes within the breast and possibly an
abnormality.
 Mammography may detect very small, non-palpable lesions
that could be benign or malignant but there is an average of 10
to 15 percent of tumors that may not be detectable.
 Mammography exposes a woman to radiation and are not as
effective for women with breast implants as it will affect how
much of the breast tissue can be seen on the screening
mammogram which will create more challenges to
radiographers to achieve clear images of the breast.

14

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED

 MARKET OVERVIEW – BREAST CANCER
ULTRASOUND
 Ultrasound Imaging of the breast produces a picture of the internal
structures of the breast. During a breast ultrasound examination, the
physician performing the test may use Doppler techniques to evaluate blood
flow or lack of flow in any breast mass. In some cases this may provide
additional information as to the cause of the mass. The sensitivity of
ultrasound is only around 60% - 88% and without objective results.
Therefore, ultrasound imaging is not the most accurate detection for breast
cancer.

15

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED

 MARKET OVERVIEW – BREAST CANCER
BIOPSY
 A breast biopsy involves the removal of some tissues—usually by a
procedure performed under anesthesia utilizing a needle which can take
small pieces of tissue from the suspicious area in the breast so that the tissue
may be examined under a microscope to confirm a diagnosis. Occasionally
a surgical biopsy is needed to make a diagnosis. Many of the areas that are
thought to be of concern turn out to be non-cancerous on biopsy

16

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED

 MARKET OVERVIEW – BREAST CANCER
TECHNOLOGY DETECTION COMPARISON

Non-invasive Painless Objective Result Instant Report Sensitivity Estimated Cost

BDS     90-95% US$35
Mammography    
78-90% US$120-350
Ultrasound     60-80% US$80-120
Biopsy    
65-98% US$320-650

17

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED

 MARKET OVERVIEW – CERVICAL
CANCER
 From the research of Oncology Channel®, Cancer of the cervix is the second
most common cancer in women worldwide and is a leading cause of cancer-
related death in women in underdeveloped countries. Worldwide,
approximately 500,000 cases of cervical cancer are diagnosed each year.
 Routine screening has decreased the incidence of invasive cervical cancer in
the United States, where approximately 13,000 cases of invasive cervical
cancer and 50,000 cases of cervical carcinoma in situ (i.e., localized cancer)
are diagnosed yearly.
 Cervical cancer detection represents a sales opportunity in excess of US$ 1
billion per year.

18

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED

 MARKET OVERVIEW – CANCER
SCREENING
 It is estimated that 1.3 million people in the U.S. were diagnosed with cancer
in 2003, and that 1 in 4 deaths was due to the disease. In the fight against
cancer, which is the second-leading cause of death in the U.S. after heart
disease, remarkable advances have been made in developing sophisticated
tools to detect malignancies at their earliest and most treatable stages.
 In 2002 more than 172.5 million cancer screening and diagnostic procedures
were performed utilizing imaging, in vitro diagnostic testing, and tissue
biopsy. These procedures generated approximately US$ 2.7 billion in
corresponding product sales, with oncology-related imaging system sales
accounting for 53.5% of the total, imaging contrast agents and
biopharmaceuticals for 20.4%, biomolecular cancer marker testing products
for 11.6%, automated Pap smear preparation/screening systems for 9.1%, and
minimally invasive biopsy devices for 5.4%. Nucleosomic™ diagnostic is
believed to be able to penetrate these different sectors in the field of cancer
screening after product launch.
19

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED

 MARKET OVERVIEW – PERSONALIZED
MEDICINE
 Current research into pharmacogenetics is concentrating on identifying the
genes that cause variations in the way that people to respond to existing
drugs.
 Pharmaceutical giants focus on totally new drugs designed with specific
genetic profiles in mind. Instead of pharmaceutical companies pursuing a
'one drug fits all' philosophy, there will be subsets of drugs, each designed
with specific individuals or populations in mind. Currently, it is estimated
that to develop a new drug, US$ 500 million has to be invested. Although,
the prospect of more drugs, each with a smaller market share, may seem to
be still in the early stage of development, the pharmaceutical giants are
happy to invest and refine the target audience of their existing drugs.
Therefore, they require substantial lab testing tools to develop new drugs
with only genetic minority 'customers' in mind.

20

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED

 5 YEAR BUSINESS DEVELOPMENT PLAN –
DISTRIBUTION
 The MacKay Medical Group Limited
 Singed Exclusive Distribution Agreement for Hong Kong and Macau
 Working with Dr. Louis Chow – Executive Director of Organization for
Oncology and Translational Research Limited (“OOTR”), on clinical trials for
Screening and Diagnostic on the BDS in HK and plans to expand the trials to
Taiwan, Beijing, Shanghai and Guangdong.
 Organizing a “Breast Cancer Awareness” campaign with HK Cancer Funds, and
Financial Times.
 Organizing a “Macau Breast Cancer Awareness” campaign with Melco Crown
Entertainment and OOTR.
 Aligning with All China Women’s Federation to co-ordinate a nationwide road
show on the BDS screening technology and HPV diagnostic test.

21

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED

 5 YEAR BUSINESS DEVELOPMENT PLAN –
DISTRIBUTION CONT.
 The MacKay Eastern Limited
 Singed Exclusive Distribution Agreement for Philippines
 Working and lobbying with The Quezon City Health Department to launch a
public breast cancer detection program for civil servants sponsored by the
Government.
 Negotiation with X-Pharma to formalize a distribution platform to create a panel
doctor scheme with over 1,200 doctors via their nationwide pharmacy-health
stores and health centers.

22

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED

 5 YEAR BUSINESS DEVELOPMENT PLAN –
DISTRIBUTION CONT.
 Palex Medical, SA.
 Signed Letter of Intent to develop a two month Clinical Trial Road Show through
Spain for the BDS screening and diagnostic technology.
 Palex has agreed to sign an Exclusive Distribution Agreement for Spain, Portugal
and Adorra.
 The MacKay Life Sciences de Mexico S.A. de C.V. (“MILSM”)
 Signed an Exclusive Distribution Agreement for US$ 1 Million covering the
following countries:
 Aruba / Belize / Costa Rica / Cuba / Dominican Republic / El Salvador / Guadeloupe /
Guatemala / Haiti / Honduras / Martinique / Mexico / Netherlands Antilles / Nicaragua /
Puerto Rico / Saint Martin / Saint Pierre & Miquelon
 Conducted a presentation to the Ministry of Health, the Sanitary Regulation
Commissioner of COFERIS the Mexican Regulatory Approvals Authority, the
Medical Director of Social Security and The National Cancer Institute which
resulted in full support from all the participants and the plan is to establish and
prepare four test sites for testing the screening and diagnostic effectiveness of the
BDS technology. 23
 Signed a Distribution MOU for Argentina and Brazil for US$ 2 Million.

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED

 5 YEAR BUSINESS DEVELOPMENT PLAN –
FUTURE DEVELOPMENT
 Manufacturing: To setup in China
 Distribution Roll-out:
 In negotiation: ASEAN / Russia / Turkey, Slovakia / United Arab Emirates
 Five Year Roll-out Plan: South Korea / Japan / India / Other Middle Eastern
Countries / South Africa / Australia / New Zealand / France / Italy / Germany /
United Kingdom / United States of America
 Research and Development
 MacKay is working with ValiRx Plc to build its own R & D centres in China and
the Philippines.
 Distribution Rights:
 Guided Therapeutics, Inc.
 Infrascan, DNC.
 Premier Heart, LLC.

24

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED

 ABOUT GUDIED THERAPEUTICS, INC.
 LightTouchTM – a non-invasive test that has the potential
to improve significantly the early detection of cervical
pre-cancers and cancers. It is a fast, painless test that,
unlike Pap smears and HPV testing, does not require a
tissue sample or the delay of obtaining laboratory
analysis.

 A pre-pivotal clinical study of LightTouchTM, sponsored

by the National Cancer Institute in the U.S. indicated
that the non-invasive test could reduce by 55% the
number of unnecessary follow-up procedures as a result
of false positive Pap test results. The potential saving to
the U.S. healthcare system could be as high as US$ 181
million annually if the technology is widely adopted.
25

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED

 ABOUT INFRASCAN DNC.
 The Infrascanner™ is a hand-held, non-invasive, near-infrared (NIR)
based mobile imaging device designed to detect brain hematoma at the site
of injury within the “golden hour”. This refers to the period following head
trauma when pre-hospital analysis is needed to assess rapidly the
neurological condition of a victim. Pending FDA clearance, the
Infrascanner™ will be an affordable, accurate and clinically effective
screening solution for head trauma patients in settings where timely triage is
critical. It is intended to aid the decision whether to proceed with other tests
such as head Computed Tomography (CT) scans. In environments where
access to CT scanning is restricted or not available, Infrascanner™ will
facilitate surgical intervention decisions.

26

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED

 ABOUT PREMIER HEART, LLC.
 Premier Heart's MCG System represents a radical departure from traditional
resting and stress ECG techniques. Where historically medicine has taken a
reductionistic view, ECG Premier Heart's MCG technology uses an
integrative approach, building a mathematical model of the entire cardiac
system. This approach allows MCG to obtain accurate diagnoses from a
simple, non-invasive test.
 When compared to other diagnostic modalities MCG is extremely accurate
and reliable, surpassing many established clinical techniques in both
sensitivity and specificity. In addition, MCG is capable of accurately
detecting coronary artery disease at an early stage (<70% lumen
encroachment), exceeding the capabilities of many other techniques and
allowing intervention at early stages where coronary disease may be
controlled by lifestyle changes or medication.

27

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED

 OUR PARTNERS

Lead-Lok, Inc.

28

Copyright © 2009 MacKay Life Sciences, Inc. ALL RIGHTS RESERVED